Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 6Recruiting 4Terminated 2Withdrawn 1Unknown 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Biphenotypic, Acute 14Recurrence 13Myelodysplastic Syndromes 13Leukemia 12Burkitt Lymphoma 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelomonocytic, Chronic 6Lymphoma, Mantle-Cell 5Neoplasm, Residual 4Myeloproliferative Disorders 4Lymphoma, Large B-Cell, Diffuse 4Hodgkin Disease 4Hematologic Neoplasms 4Sarcoma, Myeloid 3Lymphoma, T-Cell 3Lymphoma 3Blast Crisis 3Lymphoma, Non-Hodgkin 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid 2Down Syndrome 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Anemia, Refractory, with Excess of Blasts 2Targeted Therapy 1Pyloric Stenosis, Hypertrophic 1Neurofibromatosis 1 1Neoplasms by Histologic Type 1

Interventions

Cyclophosphamide 7venetoclax 6Azacitidine 6fludarabine 5Cytarabine 4Blood Specimen Collection 4daratumumab 3Lenalidomide 3Daunorubicin 3tislelizumab 2fludarabine phosphate 2Rituximab 2Liquid Biopsy 2Idarubicin 2Gemtuzumab 2Capecitabine 2Busulfan 2trastuzumab deruxtecan 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sugemalimab 1sacituzumab govitecan 1relugolix 1pembrolizumab 1pegaspargase 1palbociclib 1obinutuzumab 1ivosidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Neoplasm, Residual × Cytarabine × Clear all
NCT07059975 2025-11-04

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Baylor College of Medicine

Phase EARLY_PHASE1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Institute of Hematology & Blood Diseases Hospital, China

Phase NA Recruiting
120 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05959720 2025-05-07

BRALLA

Instituto do Cancer do Estado de São Paulo

Recruiting
180 enrolled
LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02724163 2021-10-08

Myechild01

University of Birmingham

Phase 3 Recruiting
700 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡